Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
54 hedge funds and large institutions have $4.93M invested in Navidea Biopharmaceuticals Inc. in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 7 closing their positions.
350% more call options, than puts
Call options by funds: $18K | Put options by funds: $4K
4% less funds holding
Funds holding: 56 → 54 (-2)
14% less capital invested
Capital invested by funds: $5.76M → $4.93M (-$834K)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$107K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$64.7K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$40.6K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$33.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$76.9K |
| 2 |
Goldman Sachs
New York
|
-$54.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$46K |
| 4 |
SIM
Spark Investment Management
New York
|
-$44K |
| 5 |
Jane Street
New York
|
-$42.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
51
Spark Investment Management
New York
| – | -$44K | -5,312 | Closed |
|
|
SI
52
SII Investments
Appleton,
Wisconsin
| – | -$30K | -3,551 | Closed |
|
53
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$29K | -3,500 | Closed |
|
54
Millennium Management
New York
| – | -$25K | -2,971 | Closed |
|
|
SIAS
55
Shine Investment Advisory Services
Lone Tree,
Colorado
| – | -$8K | -980 | Closed |
|
56
Wolverine Trading
Chicago,
Illinois
| – | -$6K | -757 | Closed |
|
|
IA
57
IFP Advisors
Tampa,
Florida
| – | -$423 | -50 | -50% |
|
NAVB Hedge Fund Activity: Q4 2017 in Review
54 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2017, worth a combined $4.93M — down 14% from $5.76M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NAVB and 5 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $107K. The largest seller was Sowell Financial Services, cutting an estimated $76.9K.
- 54 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2017, down from 56 in Q3 2017.
- Funds reported $4.93M of Navidea Biopharmaceuticals Inc. stock for Q4 2017, down 14% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2017 and 7 closed out, a net change of -2 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2017 was Vanguard Group, an estimated $107K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2017 was Sowell Financial Services, an estimated $76.9K sold.
Based on aggregated 13F filings for Q4 2017.